Navigation Links
Targanta Study Shows Oritavancin Treatment Effective in a Mouse,Model of Anthrax

Single-Dose Protection Observed Prior to or Up to 24 Hours After Exposure to Anthrax

TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- Targanta Therapeutics Corporation announced today the results from a recent study demonstrating oritavancin as a potential therapy for treating exposure to Bacillus anthracis, the bacterium which causes anthrax, an acute infectious disease. Oritavancin, a novel semi- synthetic lipoglycopeptide antibiotic for the treatment of serious gram- positive infections, is Targanta's lead product currently in post-Phase 3 clinical development. This research was conducted and presented in partnership with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at the American Society for Microbiology (ASM) 107th Annual General Meeting in Toronto, Ontario from May 21-25, 2007.

"We are encouraged by the research demonstrating that oritavancin may represent a potential treatment for anthrax exposure," said Thomas Parr, Ph.D., Chief Scientific Officer, Targanta Therapeutics. "This research eventually could lead to better protection for both military personnel and citizens against an anthrax attack."

Study Methods and Results:

Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax

Using an aerosol-anthrax mouse model, researchers investigated oritavancin (ORI) as potential therapy for inhalational anthrax (post-exposure). In the model, mice were exposed to spores of the Ames strain of B. anthracis at seventy five times the lethal dose necessary to kill 50% of untreated mice (75 x LD50). The control group received either saline or 30 mg/kg of ciprofloxacin (CIP) intraperitoneally (within the abdominal cavity) every 12 hours for 14 days. ORI doses ranged from 0.1 to 30 mg/kg intraperitoneally every 48 hours for 14 days. Alternatively, ORI was administered intravenously from 5 to 50 mg/kg as a single intravenous dose. All
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:5/24/2013)... , May 24, 2013  An international roster ... Saturday, May 18, in Santa Monica, Calif. ... new lung-sparing therapies for MPM, a rare form of ... affects the pleura, the lining of the chest. ... and Blood Institute, the 3rd Annual International Symposium on ...
(Date:5/24/2013)... 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Deutsche Bank Health Care Conference to be held ... Adrian Adams , Chief Executive Officer ... the Company and its product pipeline at 12:00 p.m. ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation will ...
(Date:5/24/2013)... The potential of the pulmonary route as ... has been receiving undeniable attention with the recent advances ... crucial formulation considerations for orally inhaled products together with ... in the efficiency of pulmonary delivery, and great strides ... techniques and devices in recent years. With ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... and cesarean section trials in conjunction with David ... G. Genecov, MD, FACS, FAAP to begin immediately, ... BIEL), the maker of the ActiPatch(TM), a drug free ... pulse therapy specifically designed to speed healing, today,announced world ...
... CARMEL, Israel, May 28 , - Study ... Non-Invasive,MRgFUS to Those who had Invasive Fibroid Surgery, ... Food and Drug,Administration (FDA) cleared the company to ... safety of the ExAblate(R) 2000 system utilizing,MR-guided Focused ...
Cached Medicine Technology:BioElectronics Announces Major Clinical Trials 2BioElectronics Announces Major Clinical Trials 3BioElectronics Announces Major Clinical Trials 4FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids 2FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids 3FDA Clears ExAblate Fertility Enhancement Study in Women With Uterine Fibroids 4
(Date:5/25/2013)... 25, 2013 Imagine running the air conditioner ... loss, hot air and wasted energy! If the home has ... fireplace or clothes dryer, that may be just what is ... often overlooked holes waste energy in the form of higher ... cooling loss in the home. , Drafts occur through the ...
(Date:5/25/2013)... AZ (PRWEB) May 25, 2013 An ... service page in partnership with JD Media Surge, LLC. ... methods are now available and, depending on the treatment, ... During a routine visit, the best method will be ... is performed during a visit. A special peroxide-based whitening ...
(Date:5/25/2013)... May 25, 2013 Actos lawsuit ... in U.S. District Court, Western District of Louisiana, continue ... to a Case Management Order issued on May 21st, ... of contested motions in the Actos bladder cancer litigation, ... re: Actos Product Liability Litigation, MDL No. 2299) , ...
(Date:5/25/2013)... Forney, United States (PRWEB) May 25, 2013 ... oldest and largest underground shelter company in the ... and composite underground structures for over 35 years. ... of PROTECTION, U.S. Handbook of NBC Weapon Fundamentals ... is the United States’ bible on shelter engineering. ...
(Date:5/25/2013)... May 25, 2013 On May 20, 2013 ... do not wish to discuss or plan for their eventual ... FuneralFinancials.com released a Must-Do List to help people ... Financials recommends, “Creating a personal fact sheet.” , While not ... financial information and personal data. It may include a ...
Breaking Medicine News(10 mins):Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 2Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 3Health News:How To Stop Drafts and Save On Home Energy Bills This Summer - New Draft Stoppers Now Available From Battic Door Energy Conservation 4Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2
... Genetic Testing IndustryWALTHAM, Mass., Feb. 2 Interleukin ... that Chief Executive Officer Lewis H. Bender will ... Financial Strategies for Molecular Diagnostics conference, taking place ... presentation is scheduled for Wednesday, February 4 at ...
... Ask for Provisions in Stimulus Package to Help ... than 57,000 new jobs, 26,800 of which will ... in the United States through the Renewable ... to Congress and the Administration by Health Care ...
... 2 AMDL, Inc. (NYSE,Alternext US: ADL), a vertically ... announced today its Chairman and CEO Mr.,Douglas MacLellan will ... (3:40 a.m.,PT) today, February 2, 2009. , ... expert on Fox Business News to,discuss the current business ...
... to Florida to Open its Doors, with Ceremonies at 103,000-Square-Foot Facility ... ... 2009 -- More than 200 community, government and science leaders celebrated ... Studies, (TPIMS) headquarters in the Florida Center for Innovation at ...
... Network" to serve Healthcare Industry , ... ... Marketing Solutions LLC today announced partnerships with several leading ... MindSet,s geoMEDICX Zip+4 and Zip code targeting tags and offer ...
... ... Denver, CO (PRWEB) February 2, 2009 -- Susan Cordts, ... in an exclusive interview with Mary Jo Nott and the BeyeNETWORK ... predict who to target with what product, identifying what media with ...
Cached Medicine News:Health News:Interleukin Genetics to Present at G-2 Reports' Molecular Diagnostic Conference 2Health News:Healthcare Sector Leaders Urge Obama, Congress to Invest in Alternative Energy and Green Jobs in Healthcare 2Health News:Healthcare Sector Leaders Urge Obama, Congress to Invest in Alternative Energy and Green Jobs in Healthcare 3Health News:AMDL Chairman & CEO Mr. Douglas MacLellan Featured on Fox Business News Monday February 2, 2009 2Health News:Torrey Pines Institute for Molecular Studies Opens New Headquarters in Florida 2Health News:Torrey Pines Institute for Molecular Studies Opens New Headquarters in Florida 3Health News:Mindset Marketing Solutions Partners with Platform-A, ValueClick Media, AdRX Media, Datran Media and Morefocus Media 2Health News:Mindset Marketing Solutions Partners with Platform-A, ValueClick Media, AdRX Media, Datran Media and Morefocus Media 3Health News:ATi Tailored BI and Advanced Predictive Analytics Solutions Improve Marketing Response Rates 2Health News:ATi Tailored BI and Advanced Predictive Analytics Solutions Improve Marketing Response Rates 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: